The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: Results of a phase Ib dose-escalation, open-label study

British Journal of Cancer

Volumn 103, Issue 3, 2010, Pages 332-339

  Molife, L R ^a   Fong, P C ^a   Paccagnella, L ^b   Reid, A H M ^a   Shaw, H M ^a   Vidal, L ^a   Arkenau, H T ^a   Karavasilis, V ^a   Yap, T A ^a   Olmos, D ^a   Spicer, J ^a   Postel Vinay, S ^a   Yin, D ^b   Lipton, A ^c   Demers, L ^c   Leitzel, K ^c   Gualberto, A ^b   De Bono, J S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Pf Izer Oncology   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

chemosensitisation; docetaxel; figitumumab (CP 751,871); insulin like growth factor type 1 receptor (IGF IR); monoclonal antibody

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; FIGITUMUMAB; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER PAIN; CELLULITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; TUMOR CELL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELLULITIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHOPENIA; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; TAXOIDS;

EID: 77955049754     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605767     Document Type: Article

References (28)

1. Abe S, Funato T, Takahashi S, Yokoyama H, Yamamoto J, Tomiya Y, Yamada-Fujiwara M, Ishizawa K, Kameoka J, Kaku M, Harigae H, Sasaki T (2006) Increased expression of insulin-like growth factor 1 is associated with Ara-C resistance in leukemia. Tohoku J Exp Med 209: 217-228
2. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10: 6897-6904
3. Benini S, Manara MC, Baldini N, Cerisano V, Massimo S, Mercuri M, Lollini PL, Nanni P, Picci P, Scotlandi K (2001) Inhibition of insulinlike growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 7: 1790-1797
4. Carden CP, Molife LR, de Bono JS (2009) Predictive biomarkers for targeting insulin-like growth factor receptor type I. Mol Cancer Ther 8: 2077-2078
5. Cardillo MR, Monti S, Di Silverio F, Gentile V, Sciarra F, Toscano V (2003) Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res 23: 3825-3835
6. Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, Lee HY (2002) Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 8: 3669-3675 (Pubitemid 35424756)
7. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11: 2063-2073
8. de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connely M, Terstappen LW, Gualberto A (2007) Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 13: 3611-3616
9. De Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14: 6302-6309
10. Durai R, Yang W, Gupta S, Seifalian AM, Winslet MC (2005) The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis 20: 203-220
11. Espaŕ?s-Ogando A, Ocaña A, Rodŕ?guez-Barrueco R, Ferreira L, Borges J, Pandiella A (2008) Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Ann Oncol 19: 1860-1869
12. Gibaldi M, Perrier D (1982) Noncompartmental analysis based on statistical moment theory. In Pharmacokinetics. Marcel Dekker: New York, NY, pp 409-417
13. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS (2007) Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 13: 5834-5840
14. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulinlike growth factor-I and risk of breast cancer. Lancet 351: 1393-1396 (Pubitemid 28209997)
15. Hellawell GO, Ferguson DJ, Brewster SF, Macaulay VM (2003) Chemo-sensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor. BJU Int 91: 271-277
16. Hidalgo M, Tirado Gomez M, Lewis N, Vuky JL, Taylor G, Hayburn JL, Hsu K, Kosh M, Picozzi VJ (2008) A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol 26(Suppl): 158s Abstract 3520
17. Kalli KR, Falowo OI, Bale LK, Zschunke MA, Roche PC, Conover CA (2002) Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology 143: 3259-3267
18. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein Jr G, Johnson FM, Green S, Gualberto A (2009) Phase II study of the anti-insulin-like growth factor type 1 receptor antibody, CP-751,871, in combination with paclitaxel and carboplatin in previously untreated, locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 27: 2516-2522
19. Kurmasheva RT, Houghton PJ (2006) IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 1766: 1-22
20. Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez SM, Pollak M, Jagannath S, Richardson P, Gualberto A (2008) Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulin-like growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 26: 3196-3203
21. Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Carden CP, Reid AH, A'Hern R, Fong PC, Oomen NB, Molife R, Dearnaley D, Parker C, Terstappen LW, de Bono JS (2009) Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 20: 27-33
22. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928
23. Pollak MN, Lacy MQ, Lipton A, Demers L, Leitzel K, de Bono JS, Yin D, Roberts L, Sharma A, Gualberto A (2007) Pharmacodynamic properties of the anti-IGF-IR monoclonal antibody CP-751,871 in cancer patients. J Clin Oncol 25(Suppl): 159s Abstract 3587
24. Samani AA, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28: 20-47
25. Sarantopoulos J, Mita AC, Mulay M, Romero O, Lu J, Capilla F, Chen L, Hwang Y, Friberg G, Rosen LS (2008) A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G). J Clin Oncol 26(Suppl): 173s Abstract 3583
26. Tolcher AW, Patnaik A, Till E, Takimoto CH, Papadopoulos KP, Massard C, Mery-Mignard D, Deslandes A, Ozoux M, Soria J (2008) A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor 1 receptor) antagonist, in patients (pts) with advanced solid tumor (ST). J Clin Oncol 26(Suppl): 173s Abstract 3582
27. Tolcher AW, Rothenberg ML, Rodon J, Delbeke D, Patnaik A, Nguyen L, Young F, Hwang Y, Haqq C, Puzanov I (2009) Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor receptor 1. J Clin Oncol 27: 5800-5807
28. Yin D, Tamaki N, Parent AD, Zhang JH (2005) Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity. Neurol Res 27: 27-35